Akeso, Inc. (HKG:9926)
93.60
-1.45 (-1.53%)
Sep 10, 2026, 4:08 PM HKT
Akeso Employees
Akeso had 4,082 employees as of June 30, 2026. The number of employees increased by 321 or 8.53% since the number was reported on December 31, 2025.
Employees
4,082
Change
321
Growth
8.53%
Revenue / Employee
975.85K HKD
Profits / Employee
-273.53K HKD
Market Cap
86.22B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 4,082 | 321 | 8.53% |
| Dec 31, 2025 | 3,761 | 726 | 23.92% |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| Innovent Biologics | 8,754 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
Akeso News
- 10 days ago - 'Guided missile‘ for cancer: Akeso on its bispecific antibody-drug strategy - CNBC
- 13 days ago - Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's - PRNewsWire
- 14 days ago - Akeso Earnings release: H1 2026 - Filings
- 14 days ago - China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial - South China Morning Post
- 20 days ago - Akeso's AK157D1 Cleared For Phase I Trial In Solid Tumors - Nasdaq
- 20 days ago - Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline - PRNewsWire
- 24 days ago - Summit says Akeso receives marketing authorization in China for ivonescimab - TheFly
- 4 weeks ago - Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - PRNewsWire